Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.
Cerevance has raised $20.0M in total funding. The most recent round was Series C. The last funding was announced in May 2026.
Cerevance's investors include Dementia Discovery Fund, Foresite Capital, Takeda, SV Health Investors, Lightstone Ventures.
Cerevance is headquartered in Boston, United States.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.
Cerevance is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cerevance — Funding & Investors." VCBacked, May 12, 2026, https://www.vcbacked.co/company/cerevance. Accessed September 16, 2026.
VCBacked. (2026). Cerevance — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/cerevance
{{cite web |title=Cerevance — Funding & Investors |url=https://www.vcbacked.co/company/cerevance |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated